122 related articles for article (PubMed ID: 38058082)
1.
Yang J; Jiang X; Chen Y; Teng L
Discov Med; 2023 Dec; 35(179):1167-1176. PubMed ID: 38058082
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-577/EIF5A2 axis suppressed the proliferation of DDP-resistant nasopharyngeal carcinoma cells by blocking TGF-β signaling pathway.
Wu R; Zhong Q; Liu H; Liu S
Chem Biol Drug Des; 2023 Oct; 102(4):815-827. PubMed ID: 37500510
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of LncRNA UCA1 by TGF-β promotes doxorubicin resistance in breast cancer cells.
Wo L; Zhang B; You X; Hu Y; Gu Z; Zhang M; Wang Q; Lv Z; Zhao H
Immunopharmacol Immunotoxicol; 2022 Aug; 44(4):492-499. PubMed ID: 35332839
[TBL] [Abstract][Full Text] [Related]
4. Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway.
Li X; He J; Ren X; Zhao H; Zhao H
Diagn Pathol; 2020 Dec; 15(1):141. PubMed ID: 33308276
[TBL] [Abstract][Full Text] [Related]
5. EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo.
Wei JH; Cao JZ; Zhang D; Liao B; Zhong WM; Lu J; Zhao HW; Zhang JX; Tong ZT; Fan S; Liang CZ; Liao YB; Pang J; Wu RH; Fang Y; Chen ZH; Li B; Xie D; Chen W; Luo JH
Br J Cancer; 2014 Apr; 110(7):1767-77. PubMed ID: 24504366
[TBL] [Abstract][Full Text] [Related]
6. Interactions Between
Wang S; Cheng M; Zheng X; Zheng L; Liu H; Lu J; Liu Y; Chen W
Onco Targets Ther; 2020; 13():13159-13170. PubMed ID: 33380806
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
8. EIF5A2 Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Growth by Modulating TGF- Signals.
Hao F; Zhu Q; Lu L; Sun S; Huang Y; Zhang J; Liu Z; Miao Y; Jiao X; Chen D
Oncol Res; 2020 Sep; 28(4):345-355. PubMed ID: 32138807
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
[TBL] [Abstract][Full Text] [Related]
10. N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation.
Yang J; Yu H; Shen M; Wei W; Xia L; Zhao P
Cancer Sci; 2014 Feb; 105(2):219-27. PubMed ID: 24262005
[TBL] [Abstract][Full Text] [Related]
11. microRNA-15a-5p suppresses hypoxia-induced tumor growth and chemoresistance in bladder cancer by binding to eIF5A2.
Yang J; Xiang H; Cheng M; Jiang X; Chen Y; Zheng L; Yan S; Zhang S; Zhang C; Chen W; Chen D
Neoplasma; 2024 Feb; 71(1):60-69. PubMed ID: 38506035
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition.
Guan X; Gu S; Yuan M; Zheng X; Wu J
Oncol Lett; 2019 Dec; 18(6):5986-5994. PubMed ID: 31788073
[TBL] [Abstract][Full Text] [Related]
13. Isorhamnetin induces cell cycle arrest and apoptosis by triggering DNA damage and regulating the AMPK/mTOR/p70S6K signaling pathway in doxorubicin-resistant breast cancer.
Yang T; Xiao Y; Liu S; Luo F; Tang D; Yu Y; Xie Y
Phytomedicine; 2023 Jun; 114():154780. PubMed ID: 37004402
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA TUG1 decreases bladder cancer chemo-sensitivity toward doxorubicin through elevating KPNA2 expression and activating the PI3K/AKT pathway via adsorbing miR-582-5p.
Lu P; Jiang Y; Xia Z
Anticancer Drugs; 2023 Jan; 34(1):144-154. PubMed ID: 36539367
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
Smolensky D; Rathore K; Cekanova M
BMC Cancer; 2015 Nov; 15():927. PubMed ID: 26597249
[TBL] [Abstract][Full Text] [Related]
16. Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-β signalling pathway.
Dong Y; Ding D; Gu J; Chen M; Li S
Bioengineered; 2022 Jun; 13(6):14282-14298. PubMed ID: 35746836
[TBL] [Abstract][Full Text] [Related]
17. Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition.
Bao Y; Lu Y; Wang X; Feng W; Sun X; Guo H; Tang C; Zhang X; Shi Q; Yu H
Cancer Cell Int; 2015; 15():109. PubMed ID: 26581310
[TBL] [Abstract][Full Text] [Related]
18. CD151 promotes breast cancer metastasis by activating TGF-β1/Smad signaling pathway.
Zhao SJ; Zhao HD; Li J; Zhang H; Gao DT; Wang Q
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7314-7322. PubMed ID: 30468476
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma.
Zhang H; Guo Y; Song Y; Shang C
Cancer Chemother Pharmacol; 2017 Jan; 79(1):49-55. PubMed ID: 27878359
[TBL] [Abstract][Full Text] [Related]
20. Sonic Hedgehog-GLI Family Zinc Finger 1 Signaling Pathway Promotes the Growth and Migration of Pancreatic Cancer Cells by Regulating the Transcription of Eukaryotic Translation Initiation Factor 5A2.
Xu X; Liu H; Zhang H; Dai W; Guo C; Xie C; Wei S; He S; Xu X
Pancreas; 2015 Nov; 44(8):1252-8. PubMed ID: 26465952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
